CSL Limited ready for China

Matthew Haupt

Wilson Asset Management

On Tuesday, CSL Limited (ASX: CSL) announced its decision to acquire 80% of the equity of plasma-derived therapies manufacturer, Wuhan Zhong Yuan Rui De Biological Products (Ruide) in China for US $352 million. The transaction will see the company enter the Chinese domestic plasma fractionation market. CSL Limited has demonstrated significant earnings momentum in FY17, and we see this continuing into the new financial year. Shares in CSL Limited closed up 2.9% for the week. We own CSL Limited as a market-driven investment in WAM Leaders.


Matthew Haupt
Lead Portfolio Manager
Wilson Asset Management

Matthew has more than 15 years’ experience in the investment industry working as both a portfolio manager and analyst. Matthew is the Lead Portfolio Manager responsible for WAM Leaders.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.